[en] Imaging neurotransmission in vivo using positron emission tomography (PET) is a rapidly expanding clinical science. The present review summarizes the actual contribution of PET imaging to clinical problems in movement and seizure disorders and dementia.
Research Center/Unit :
GIGA CRC (Cyclotron Research Center) In vivo Imaging-Aging & Memory - ULiège
Disciplines :
Neurosciences & behavior Radiology, nuclear medicine & imaging Neurology
Author, co-author :
Garraux, Gaëtan ; Université de Liège - ULiège > Centre de Recherches du Cyclotron et Département des sciences cliniques > Neurologie
Salmon, Eric ; Université de Liège - ULiège > Centre de Recherches du Cyclotron et Département des sciences cliniques > Neurologie
Language :
English
Title :
Clinical contribution of PET neurotransmission imaging in neurological disorders
Albin R. L., Koeppe R. A., Bohnen N. I., Nichols T. E., Meyer P. et al. Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology, 2003, 61: 310-315.
Antonini A., Leenders K. L., Spiegel R., Meier D., Vontobel P. et al. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain, 1996, 119 (Pt 6): 2085-2095.
Antonini A., Leenders K. L., Vontobel P., Maguire R. P., Missimer J. et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain, 1997, 120: 2187-2195.
Arnold S., Berthele A., Drzezga A., Tolle T. R., Weis S. et al. Reduction of benzodiazepine receptor binding is related to the seizure onset zone in extratemporal focal cortical dysplasia. Epilepsia, 2000, 41: 818-824.
Babb T. L., Brown W. J., Pretorius J., Davenport C., Lieb J. P. et al. Temporal lobe volumetric cell densities in temporal lobe epilepsy. Epilepsia, 1984, 25: 729-740.
Banati R. B., Myers R., Kreutzberg G. W. PK ('peripheral benzodiazepine') - binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H]PK11195 binding to activated microglia. J. Neurocytol., 1997, 26: 77-82.
Banati R. B., Newcombe J., Gunn R. N., Cagnin A., Turkheimer F. et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain, 2000, 123 (Pt 11): 2321-2337.
Berkovic S. F., McIntosh A. M., Kalnins R. M., Jackson G. D., Fabinyi G. C. et al. Preoperative MRI predicts outcome of temporal lobectomy: an actuarial analysis. Neurology, 1995, 45: 1358-1363.
Blin J., Baron J. C., Dubois B., Crouzel C., Fiorelli M. et al. Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone. Brain, 1993, 116 (Pt 3): 497-510.
Bohnen N. I., Koeppe R. A., Meyer P., Ficaro E., Wernette K. et al. Decreased striatal monoaminergic terminals in Huntington disease. Neurology, 2000, 54: 1753-1759.
Bondareff W., Mountjoy C. Q., Roth M. Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology, 1982, 32: 164-168.
Braak H., BRAAK E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl), 1991, 82: 239-259.
Braune S., Reinhardt M., Schnitzer R., Riedel A., Lucking C. H. Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology, 1999, 53: 1020-1025.
Brooks D. J., Ibanez V., Sawle G. V., Quinn N., Lees A. J. et al. Differing Patterns of Striatal 18F-Dopa Uptake in Parkinson's Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy. Ann. Neurol., 1990a, 28: 547-555.
Brooks D. J., Salmon E., Mathias C. J., Quinn N. P., Leenders K. L. et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain, 1990b, 113: 1539-1552.
Brooks D. J., Ibanez V., Playford E. D., Sawle G. V., Leigh P. N. et al. Presynaptic and postsynaptic striatal dopaminergic function in neuroacanthocytosis: a positron emission tomographic study. Ann. Neurol., 1991, 30: 166-171.
Brooks D. J., Ibanez V., Sawle G. V., Playford E. D., Quinn N. P. et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann. Neurol., 1992, 31: 184-192.
Brooks D. J. Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. J. Neurol., 2000, 247 (Suppl. 2): 1111-1118.
Brooks D. J., Piccini P. Non-invasive in vivo imaging of transplant function. Prog. Brain Res., 2000, 127: 321-332.
Brooks D. J., Frey K. A., Marek K. L., Oakes D., Paty D. et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp. Neurol., 2003, 184 (Suppl. 1): S68-S79.
Broussolle E., Lucking C. B., Ginovart N., Pollak P., Remy P. et al. [18 F]-dopa PET study in patients with juvenile-onset PD and parkin gene mutations. Neurology, 2000, 55: 877-879.
Brown W. D., Taylor M. D., Roberts A. D., Oakes T. R., Schueller M. J. et al. FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa. Neurology, 1999, 53: 1212-1218.
Burn D. J., Sawle G. V., Brooks D. J. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J. Neurol. Neurosurg. Psychiatry, 1994, 57: 278-284.
Cagnin A., Brooks D. J., Kennedy A. M., Gunn R. N., Myers R. et al. In-vivo measurement of activated microglia in dementia. Lancet, 2001a, 358: 461-467.
Cagnin A., Myers R., Gunn R. N., Lawrence A. D., Stevens T. et al. In vivo visualization of activated glia by [11C] (R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain, 2001b, 124: 2014-2027.
Calne D. B., Langston J. W., Martin W. R., Stoessl A. J., Ruth T. J. et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature, 1985, 317: 246-248.
Caparros-Lefebvre D., Cabaret M., Godefroy O., Steinling M., Remy P. et al. PET study and neuropsychological assessment of a long-lasting postencephalitic parkinsonism. J. Neural Transm., 1998, 105: 489-495.
Carson R. E., Lang L., Watabe H., Der M. G., Adams H. R. et al. PET evaluation of [(18)F]FCWAY, an analog of the 5-HT(1A) receptor antagonist, WAY-100635. Nucl. Med. Biol., 2000, 27: 493-497.
Ceravolo R., Piccini P., Bailey D. L., Jorga K. M., Bryson H. et al. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse, 2002, 43: 201-207.
Cho S., Neff N. H., Hadjiconstantinou M. Regulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase by dopaminergic drugs. Eur. J. Pharmacol., 1997, 323: 149-157.
Chugani H. T., Shields W. D., Shewmon D. A., Olson D. M., Phelps M. E. et al. Infantile spasms: I. PET identifies focal cortical dysgenesis in cryptogenic cases for surgical treatment. Ann. Neurol., 1990, 27: 406-413.
Cumming P., Ase A., Laliberte C., Kuwabara H., Gjedde A. In vivo regulation of DOPA decarboxylase by dopamine receptors in rat brain. J. Cereb. Blood Flow Metab., 1997, 17: 1254-1260.
Daniel S. E., De Bruin V. M. S., Lees A. J. The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal. Brain, 1995, 118: 759-770.
Davisk. K. L., Mohs R. C., Marin D., Purohit D. P., Perl D. P. et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA, 1999, 281: 1401-1406.
Davis. M. R., Votaw J. R., Bremner J. D., Byas-Smith M. G., Faber T. L. et al. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. J. Nucl. Med., 2003, 44: 855-861.
De Lacoste M. C., White C. L., III. The role of cortical connectivity in Alzheimer's disease pathogenesis: a review and model system. Neurobiol. Aging, 1993, 14: 1-16.
Dekosky S. T., Ikonomovic M. D., Styren S. D., Beckett L., Wisniewski S. et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann. Neurol., 2002, 51: 145-155.
Desbiens R., Berkovic S. F., Dubeau F., Andermann F., Laxer K. D. et al. Life-threatening focal status epilepticus due to occult cortical dysplasia. Arch. Neurol., 1993, 50: 695-700.
Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A. et al. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med., 2004, 351: 2498-2508.
Fearnley J. M., Lees A. J. Striatonigral degeneration. A clinicopathological study. Brain, 1990, 113: 1823-1842.
Fearnley J. M., Lees A. J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain, 1991, 114: 2283-2301.
Forno L. S., DeLanney L. E., Irwin I., Langston J. W. Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations. Adv. Neurol., 1993, 60: 600-608.
Francis P. T., Palmer A. M., Snape M., Wilcock G. K. The cholinergic hypothesis of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry, 1999, 66: 137-147.
Frey K. A., Koepp M. J., Kilbourn M. R., Vander Borght T. M., Albin R. L. et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann. Neurol., 1996, 40: 873-884.
Fuente-Fernandez R., Sossi V., Huang Z., Furtado S., Lu J. Q. et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain, 2004.
Garnett E. S., Firnau G., Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature, 1983, 305: 137-138.
Garraux G., Salmon E., Peigneux P., Kreisler A., Degueldre C. et al. Voxel-based distribution of metabolic impairment in corticobasal degeneration. Mov. Disord., 2000, 15: 894-904.
Gerhard A., Banati R. B., Cagnin A., Brooks D. J. In vivo imaging of activated microglia with [C-11]PK11195 positron emission tomography (PET) in idiopathic and atypical Parkinson's disease. Neurology, 2001, 56 (Suppl. 3): A270.
Gerhard A., Watts J., Trender-Gerhard I., Turkheimer F., Banati R. B. et al. In vivo imaging of microglial activation with [(11)C](R)-PK11195 PET in corticobasal degeneration. Mov. Disord., 2004, 19: 1221-1226.
Ghaemi M., Rudolf J., Schmulling S., Bamborschke S., Heiss W. D. FDG- and Dopa-PET in postencephalitic parkinsonism. J. Neural. Transm., 2000, 107: 1289-1295.
Ghaemi M., Hilker R., Rudolf J., Sobesky J., Heiss W. D. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multitracer PET imaging. J. Neurol. Neurosurg. Psychiatry, 2002, 73: 517-523.
Gill S. S., Patel N. K., Hotton G. R., O'Sullivan K., McCarter R. et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med, 2003, 9: 589-595.
Groom G. N., Junck L., Foster N. L., Frey K. A., Kuhl D. E. PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer's disease. J. Nucl. Med, 1995, 36: 2207-2210.
Guttman M., Stewart D., Hussey D., Wilson A., Houle S. et al. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology, 2001, 56: 1559-1564.
Hagell P., Piccini P., Bjorklund A., Brundin P., Rehncrona S. et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat. Neurosci., 2002, 5: 627-628.
Hammers A., Koepp M. J., Hurlemann R., Thom M., Richardson M. P. et al. Abnormalities of grey and white matter [11 C]flumazenil binding in temporal lobe epilepsy with normal MRI. Brain, 2002, 125: 2257-2271.
Hand K. S., Baird V. H., Van Paesschen W., Koepp M. J., Revesz T. et al. Central benzodiazepine receptor autoradiography in hippocampal sclerosis. Br. J. Pharmacol., 1997, 122: 358-364.
Hendricksen M., Thomas A.J., Ferrier I. N., Ince P., O'Brien J. T. Neuropathological study of the dorsal raphe nuclei in late-life depression and Alzheimer's disease with and without depression. Am. J. Psychiatry, 2004, 161: 1096-1102.
Herholz K., Bauer B., Wienhard K., Kracht L., Mielke R. et al. In-vivo measurements of regional al acetylcholine esterase activity in degenerative dementia: comparison with blood flow and glucose metabolism. J. Neural. Transm., 2000, 107: 1457-1468.
Hilker R., Schweitzer K., Coburger S., Ghaemi M., Weisenhach S. et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch. Neurol., 2005, 62: 378-382.
Hillen M. E., Wagner M. L., Sage J. I. "Subclinical" orthostatic hypotension is associated with dizziness in elderly patients with Parkinson disease. Arch. Phys. Med. Rehabil., 1996, 77: 710-712.
Hornykiewicz O., Kish S. J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol., 1987, 45: 19-34.
Hughes A. J., Daniel S. E., Kilford L., Lees A. J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry, 1992, 55: 181-184.
Hughes A. J., Daniel S. E., Lees A. J. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology, 2001, 57: 1497-1499.
Hyman B. T., Van Horsen G. W., Damasio A. R., Barnes C. L. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science, 1984, 225: 1168-1170.
Hyman B. T., Flory J. E., Arnold S. E., Van Hoesen G. W., Schelper R. L. et al. Quantitative assessment of ALZ-50 immunoreactivity in Alzheimer's disease. J. Geriatr. Psychiatry Neurol., 1991, 4: 231-235.
Ichinose H., Ohye T., Takahashi E., Seki N., Hori T. et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat. Genet., 1994, 8: 236-242.
Juhasz C., Chugani D.C., Muzik O., Shah A., Shah J. et al. Relationship of flumazenil and glucose PET abnormalities to neocortical epilepsy surgery outcome. Neurology, 2001, 56: 1650-1658.
Juhasz C., Chugani D. C., Padhye U.N., Muzik O., Shah A. et al. Evaluation with alpha-[11C] methyl-L-tryptophan positron emission tomography for reoperation. after failed epilepsy surgery. Epilepsia, 2004, 45: 124-130.
Kaasinen V., Ruottinen H., Någren K., Lehikoinen P., Oikonen V. J. et al. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C]Raclopride and [11C]N-Methylspiperone. J. Nucl. Med., 2000, 41: 65-70.
Kazuta T., Hayashi M., Shimizu T., Iwasaki A., Nakamura S. et al. Autonomic dysfunction in Machado-Joseph disease assessed by iodine123-labeled metaiodobenzylguanidine myocardial scintigraphy. Clin. Auton. Res., 2000, 10: 111-115.
Khan N. L., Scherfler C., Graham E., Bhatia K. P., Quinn N. et al. Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology, 2005, 64: 134-136.
Khan N. L., Valente E. M., Bentivoglio A. R., Wood N. W., Albanese A. et al. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann. Neurol., 2002, 52: 849-853.
Kishs. S. J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med., 1988, 318: 876-880.
Kishore A., Nygaard T. G., Fuente-Fernandez R., Naini A. B., Schulzer M. et al. Striatal D2 receptors in symptomatic and asymptomatic carriers of dopa-responsive dystonia measured with [11C]-raclopride and positron-emission tomography. Neurology, 1998, 50: 1028-1032.
Klunk W. E., Engler H., Nordberg A., Wang Y., Blomqvist G. et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol., 2004, 55: 306-319.
Koepp M. J., Richardson M. P., Labbe C., Brooks D. J., Cunningham V. J. et al. 11C-flumazenil PET, volumetric MRI, and quantitative pathology in mesial temporal lobe epilepsy. Neurology, 1997, 49: 764-773.
Koepp M. J., Hand K. S., Labbe C., Richardson M. P., Van Paesschen W. et al. In vivo [11C]flumazenil-PET correlates with ex vivo [3H]flumazenil autoradiography in hippocampal sclerosis. Ann. Neurol., 1998, 43: 618-626.
Kordower J. H., Freeman T. B., Snow B. J., Vingerhoets F. J., Mufson E. J. et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N. Engl. J. Med., 1995, 332: 1118-1124.
Kuhl D. E., Koeppe R. A., Minoshima. S., Snyder S. E., Ficaro E. P. et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology, 1999, 52: 691-699.
Kuhl D. E., Minoshima S., Fessler J. A., Frey K. A., Foster N. L. et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann. Neurol., 1996, 40: 399-410.
Kunig G., Leenders K. L., Antonini A., Vontobel P., Weindl A. et al. D2 receptor binding in doparesponsive dystonia. Ann. Neurol., 1998, 44: 758-762.
Kuzniecky R., Garcia J. H., Faught E., Morawetz R. B. Cortical dysplasia in temporal lobe epilepsy : magnetic resonance imaging correlations. Ann. Neurol., 1991, 29: 293-298.
Langer O., Halldin C. PET and SPET tracers for mapping the cardiac nervous system. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29: 416-434.
Langston J. W., Ballard P., Tetrud J. W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 1983, 219: 979-980.
Langston J. W., Forno L. S., Tetrud J., Reeves A. G., Kaplan J. A. et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol., 1999, 46: 598-605.
Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab., 2000, 20: 423-451.
Laureys S., Salmon E., Garraux G., Peigneux P., Lemaire C. et al. Fluorodopa uptake and glucose metabolism in early stages of corticobasal degeneration. J. Neurol., 1999, 246: 1151-1158.
Lee C. S., Samii A., Sossi V., Ruth T. J., Schulzer M. et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neurol., 2000, 47: 493-503.
Leenders K. L., Salmon E., Tyrrell P. J., Perani D., Brooks D. J. et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch. Neurol., 1990, 12: 1290-1298.
Li S. T., Dendi R., Holmes C., Goldstein D. S. Progressive loss of cardiac sympathetic innervation in Parkinson's disease. Ann. Neurol., 2002, 52: 220-223.
Lin S. K., Lu C. S., Vingerhoets F. J., Snow B. J., Wai Y. Y. et al. Isolated involvement of substantia nigra in acute transient parkinsonism: MRI and PET observations. Park. Dis. Rel. Dis., 1995, 1: 67-72.
Lyness S. A., Zarow C., Chui H. C. Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol. Aging, 2003, 24: 1-23.
Mann D. M., Yates P. O., Marcyniuk B. A comparison of changes in the nucleus basalis and locus caeruleus in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry, 1984, 47: 201-203.
Maziere M., Hantraye P., Prenant C., Sastre J., Comar D. Synthesis of ethyl 8-fluoro-5,6-dihydro-5-[11C] methyl-6-oxo-4H-imidazo [1,5-a] [1,4]benzodiazepine-3-carboxylate (RO 15.1788-11C): a specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomography. Int. J. Appl. Radiat. Isot., 1984, 35: 973-976.
Mcgeer P. L., Itagaki S., Tago H., McGeer E. G. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci. Lett., 1987, 79: 195-200.
McGeer P. L., Akiyama H., Itagaki S., McGeer E. G. Immune system response in Alzheimer's disease. Can. J. Neurol. Sci., 1989, 16: 516-527.
McGeer P. L., Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology, 1992, 42: 447-449.
Meltzer C. C., Smith G., Dekosky S. T., Pollock B. G., Mathis C. A. et al. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology, 1998, 18: 407-430.
Meltzer C. C., Price J. C., Mathis C. A., Greer P. J., Cantwell M. N. et al. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. Am. J. Psychiatry, 1999, 156: 1871-1878.
Merlet I., Ostrowsky K., Costes N., Ryvlin P., Isnard J. et al. 5-HT1A receptor binding and intracerebral activity in temporal lobe epilepsy: an [18F]MPPF-PET study. Brain, 2004, 127: 900-913.
Mesulam M. M., Geula C. Overlap between acetylcholinesterase-rich and choline acetyltransferase-positive (cholinergic) axons in human cerebral cortex. Brain Res., 1992, 577: 112-120.
Mesulam M. M. Neuroanatomy of cholinesterases in the normal human brain and in Alzheimer's disease. In : Cholinesterases and cholinesterase inhibitors. Giacobini E. (ed.). London: Martin Dunitz, 2000: 121-37.
Micieli G., Martignoni E., Cavallini A., Sandrini G., Nappi G. Postprandial and orthostatic hypotension in Parkinson's disease. Neurology, 1987, 37: 386-393.
Minoshima S., Giordani B., Berent S., Frey K. A., Foster N. L. et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol., 1997, 42: 85-94.
Morrish P. K., Sawle G. V., Brooks D. J. Clinical and [18F] dopa PET findings in early Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 1995, 59: 597-600.
Morrish P. K., Rakshi J. S., Bailey D. L., Sawle G. V., Brooks D. J. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J. Neurol. Neurosurg. Psychiatry, 1998, 64: 314-319.
Muzik O., da Silva E. A., Juhasz C., Chugani D. C., Shah J. et al. Intracranial EEG versus flumazenil and glucose PET in children with extratemporal lobe epilepsy. Neurology, 2000, 54: 171-179.
Nordberg A., Hartvig P., Lilja A., Viitanen M., Amberla K. et al. Decreased uptake and binding of 11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography. J. Neural. Transm. Park. Dis. Dement. Sect., 1990, 2: 215-224.
Nurmi E., Bergman J., Eskola O., Solin O., Hinkka S. M. et al. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study. J. Cereb. Blood Flow. Metab., 2000, 20: 1604-1609.
Nurmi E., Ruottinen H. M., Bergman J., Haaparanta M., Solin O. et al. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov. Disord., 2001, 16: 608-615.
Nygaard T. G., Takahashi H., Heiman G. A., Snow B. J., Fahn S. et al. Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with doparesponsive dystonia. Ann. Neurol., 1992, 32: 603-608.
Olsen R. W., McCabe R. T., Wamsley J. K. Gabaa receptor subtypes: autoradiographic comparison of GABA, benzodiazepine, and convulsant binding sites in the rat central nervous system. J. Chem. Neuroanat., 1990, 3: 59-76.
Orimo S., Ozawa E., Oka T., Nakade S., Tsuchiya K. et al. Different histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA. Neurology, 2001, 57: 1140-1141.
Orimo S., Oka T., Miura H., Tsuchiya K., Mori F. et al. Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J. Neurol. Neurosurg. Psychiatry, 2002, 73: 776-777.
Otsuka M., Ichiya Y., Kuwabara Y., Hosokawa S., Sasaki M. et al. Differences in the reduced 18F-DOPA uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms. J. Neurol. Sci., 1996, 136: 169-173.
Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA, 2002, 287: 1653-1661.
Pavese N., Andrews T. C., Brooks D. J., Ho A. K., Rosser A. E. et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain, 2003, 126: 1127-1135.
Petersen R. C., Stevens J. C., Ganguli M., Tangalos E. G., Cummings J. L. et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2001, 56: 1133-1142.
Piccini P., Weeks R. A., Brooks D. J. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann. Neurol., 1997, 42: 720-726.
Piccini P., Whone A. Functional brain imaging in the differential diagnosis of Parkinson's disease. Lancet Neurol., 2004, 3: 284-290.
Plenevaux A., Lemaire C., Aerts J., Lacan G., Rubins D. et al. [(18)F]p-MPPF: A radiolabeled antagonist for the study of 5-HT(1A) receptors with PET. Nucl. Med. Biol., 2000, 27: 467-471.
Przedborski S., Vila M. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann. N.Y. Acad. Sci., 2003, 991: 189-198.
Rakshi J. S., Uema T., Ito K., Bailey D. L., Morrish P. et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease. A 3D [18F]dopa-PET study. Brain, 1999, 122: 1637-1650.
Ravina B., Eidelberg D., Ahlskog J. E., Albin R. L., Brooks D. J. et al. The role of radiotracer imaging in Parkinson disease. Neurology, 2005, 64: 208-215.
Ribeiro M. J., Vidailhet M., Loc'h C., Dupel C., Nguyen J. P. et al. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch. Neurol., 2002, 59: 580-586.
Rinne J. O., Laihinen A., Ruottinen H., Ruotsalainen U., Nagren K. et al. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride. J. Neurol. Sci., 1995, 132: 156-161.
Rinne J. O., Kaasinen V., Jarvenpaa T., Nagren K., Roivainen A. et al. Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry, 2003, 74: 113-115.
Sadzot B. Neuroimaging in epilepsy: is there a future for positron emission tomography. Epilepsia, 1996, 37: 511-514.
Saiki S., Hirose G., Sakai K., Kataoka S., Hori A. et al. Cardiac 1231-MIBG scintigraphy can assess the disease severity and phenotype of PD. J. Neurol. Sci., 2004, 220: 105-111.
Salmon E., Sadzot B., Maquet P., Degueldre C., Lemaire C. et al. Differential diagnosis of Alzheimer's disease with PET. J. Nucl. Med., 1994, 35: 391-398.
Satoh A., Serita T., Seto M., Tomita I., Satoh H. et al. Loss of 1231-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. J. Nucl. Med., 1999, 40: 371-375.
Sawle G. V., Brooks D. J., Marsden C. D., Frackowiak R. S. Corticobasal degeneration. A unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. Brain, 1991a, 114 (Pt 1B): 541-556.
Sawle G. V., Leenders K. L., Brooks D. J., Harwood G., Lees A. J. et al. Dopa-responsive dystonia: [18F]dopa positron emission tomography. Ann. Neurol., 1991b, 30: 24-30.
Senard J. M., Rai S., Lapeyre-Mestre M., Brefel C., Rascol O. et al. Prevalence of orthostatic hypotension in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 1997, 63: 584-589.
Snow B. J., Nygaard T. G., Takahashi H., Calne D. B. Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism. Ann. Neurol., 1993a, 34: 733-738.
Snow B. J., Tooyama I., McGeer E. G., Yamada T., Calne D. B. et al. Human positron emission-tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann. Neurol., 1993b, 34: 324-330.
Snow B. J., Vingerhoets F. J., Langston J. W., Tetrud J. W., Sossi V. et al. Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J. Neurol. Neurosurg. Psychiatry, 2000, 68: 313-316.
Spinks T. J., Jones T., Bloomfield P. M., Bailey D. L., Miller M. et al. Physical characteristics of the ECAT EXACT3D positron tomograph. Phys. Med. Biol., 2000, 45: 2601-2618.
Stern Y., Tetrud J. W., Martin W. R., Kutner S. J., Langston J. W. Cognitive change following MPTP exposure. Neurology, 1990, 40: 261-264.
Takahashi H., Snow B. J., Nygaard T. G., Calne D. B. Clinical heterogeneity of dopa-responsive dystonia: PET observations. Adv. Neurol., 1993, 60: 586-590.
Takatsu H., Nishida H., Matsuo H., Watanabe S., Nagashima K. et al. Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. J. Nucl. Med., 2000, 41: 71-77.
Taki J., Nakajima K., Hwang E. H., Matsunari I., Komai K. et al. Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur. J. Nucl. Med., 2000, 27: 566-573.
Terry R. D., Masliah E., Salmon D. P., Butters N., DeTeresa R. et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol., 1991, 30: 572-580.
Theodore W. H. Does Serotonin Play a Role in Epilepsy? Epilepsy Curr., 2003, 3: 173-177.
Thobois S., Ribeiro M. J., Lohmann E., Durr A., Pollak P. et al. Young-onset Parkinson disease with and without parkin gene mutations: a fluorodopa F 18 positron emission tomography study. Arch. Neurol., 2003, 60: 713-718.
Tiraboschi P., Hansen L. A., Alford M., Masliah E., Thal L. J. et al. The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease. Neurology, 2000, 55: 1278-1283.
Tison F., Normand E., Jaber M., Aubert I., Bloch B. Aromatic L-amino-acid decarboxylase (DOPA decarboxylase) gene expression in dopaminergic and serotoninergic cells of the rat brainstem. Neurosci. Lett., 1991, 127: 203-206.
Toczek M. T., Carson R. E., Lang L., Ma Y., Spanaki M. V. et al. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology, 2003, 60: 749-756.
Turjanski N., Lees A. J., Brooks D. J. Dopaminergic function in patients with posttraumatic parkinsonism: an 18F-dopa PET study. Neurology, 1997a, 49: 183-189.
Turjanski N., Lees A. J., Brooks D. J. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology, 1997b, 49: 717-723.
Turner M. R., Cagnin A., Turkheimer F. E., Miller C. C., Shaw C. E. et al. Evidence of wide-spread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol. Dis., 2004, 15: 601-609.
Vandenberghe R., Vandenbulcke M., Dupont P., Bormans G., Verbruggen A. et al. Voxel-based parametric mapping of cholinesterase activity using [11C]-PMP in mild cognitive impairment. Acta Neurol. Belg., 2004, 104 (Suppl.): 62.
Vanderborght T., Kilbourn M., Desmond T., Kuhl D., Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur. J. Pharmacol., 1995, 294: 577-583.
Van Paesschen W. Ictal SPECT. Epilepsia, 2004, 45 (Suppl. 4): 35-40.
Varnas K., Halldin C., Hall H. Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum. Brain Mapp., 2004, 22: 246-260.
Vingerhoets F. J., Snow B. J., Tetrud J. W., Langston J. W., Schulzer M. et al. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann. Neurol., 1994, 36: 765-770.
Volkow N. D., Ding Y. S., Fowler J. S., Gatley S. J. Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia. Biol. Psychiatry, 2001, 49: 211-220.
Weeks R. A., Piccini P., Harding A. E., Brooks D. J. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann. Neurol., 1996, 40: 49-54.
Weihe E., Tao-cheng J. H., Schafer M. K., Erickson J. D., Eiden L. E. Visualization of the vesicular acetylcholine transporter in cholinergic nerve terminals and its targeting to a specific population of small synaptic vesicles. Proc. Natl. Acad. Sci. U.S.A, 1996, 93: 3547-3552.
Wenning G. K., Tison F., Ben Shlomo Y., Daniel S. E., Quinn N. P. Multiple system atrophy: a review of 203 pathologically proven cases. Mov. Disord., 1997, 12: 133-147.
Whitehouse P. J., Price D. L., Struble R. G., Clark A. W., Coyle J. T. et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science, 1982, 215: 1237-1239.
Whone A., Davis M., Sabolek M. The REAL-PET study: slower progression in early Parkinson's disease treated with ropinirole compared with L-dopa. Neurology, 2002, 58: A82-A83.
Whone A. L., Watts R. L., Stoessl A. J., Davis M., Reske S. et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann. Neurol., 2003, 54: 93-101.
Widner H., Tetrud J., Rehncrona S., Snow B., Brundin P. et al. Bilateral fetal mesencephalic grafting in two patients with
Wilson J. M., Kish S. J. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J. Neurosci., 1996, 16: 3507-3510.
Yoshida T., Kuwabara Y., Ichiya Y., Sasaki M., Fukumura T. et al. Cerebral muscarinic acetylcholinergic receptor measurement in Alzheimer's disease patients on 11C-N-methyl-4-piperidyl benzilate - comparison with cerebral blood flow and cerebral glucose metabolism. Ann. Nucl. Med., 1998, 12: 35-42.
Zhu M. Y., Juorio A. V., Paterson I. A., Boulton A. A. Regulation of striatal aromatic L-amino acid decarboxylase: effects of blockade or activation of dopamine receptors. Eur. J. Pharmacol., 1993, 238: 157-164.
Zubieta J. K., Koeppe R. A., Frey K. A., Kilbourn M. R., Mangner T. J. et al. Assessment of muscarinic receptor concentrations in aging and Alzheimer disease with [11C]NMPB and PET. Synapse, 2001, 39: 275-287.
